Evidence map›Paper›PMID 24921912›Full record

ArticleBritish journal of cancer2014

Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model.

B Chiu, J Coburn, M Pilichowska, C Holcroft, F P Seib, A Charest, D L Kaplan

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Delivery of eupenifeldin via polymer-coated surgical buttresses prevents local lung cancer recurrence.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

B ChiuDepartment of Surgery, University of Illinois at Chicago, 840 S. Wood Street, Suite 416, Chicago, IL 60612, USA.
J CoburnDepartment of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA.
M PilichowskaDepartment of Pathology, Tufts Medical Center, 800 Washington Street, Box 115, Boston, MA 02111, USA.
C HolcroftTufts Clinical and Translational Science Institute, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA.
F P SeibStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.
A CharestDepartment of Neurosurgery, Tufts Medical Center, 800 Washington Street, Tufts Medical Center, Box 5609, Boston, MA 02111, USA.
D L KaplanDepartment of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA.
Tufts University · USTufts Medical Center · USUniversity of Strathclyde · GB

Funding

The role of microvesicles in giloma virotherapyP01CA069246 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BREAKEFIELD, XANDRA OWENS, CHIOCCA, E. ANTONIO · 1996 to 2021
$30.9M
Tufts Clinical and Translational Research InstituteUL1TR001064 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$26.4M
Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
Tufts Clinical and Translation Science Institute (UL1)UL1TR000073 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2012 to 2013
$5.5M
Three-dimensional Human Kidney Tissue System for Studying Renal DiseasesF32DK098877 · NIDDK · TUFTS UNIVERSITY MEDFORD · PI COBURN, JEANNINE · 2013 to 2015
$151k
NCATS NIH HHS UL1 TR000073NCATS NIH HHS UL1 TR001064NCI NIH HHS P01 CA069246NIBIB NIH HHS P41 EB002520NIDDK NIH HHS F32 DK098877
6 · The paper itself

Abstract

backgroundNeuroblastoma tumour resection goal is maximal tumour removal. We hypothesise that combining surgery with sustained, local doxorubicin application can control tumour growth.

methodsWe injected human neuroblastoma cells into immunocompromised mouse adrenal gland. When KELLY cell-induced tumour volume was >300 mm(3), 80-90% of tumour was resected and treated as follows: instantaneous-release silk film with 100 μg doxorubicin (100IR), controlled-release film with 200 μg (200CR) over residual tumour bed; and 100 and 200 μg intravenous doxorubicin (100IV and 200IV). Tumour volume was measured and histology analysed.

resultsOrthotopic tumours formed with KELLY, SK-N-AS, IMR-32, SH-SY5Y cells. Tumours reached 1800±180 mm(3) after 28 days, 2200±290 mm(3) after 35 days, 1280±260 mm(3) after 63 days, and 1700±360 mm(3) after 84 days, respectively. At 3 days post KELLY tumour resection, tumour volumes were similar across all groups (P=0.6210). Tumour growth rate was similar in untreated vs control film, 100IV vs 100IR, and 100IV vs 200IV. There was significant difference in 100IR vs 200CR (P=0.0004) and 200IV vs 200CR (P=0.0003). Tumour growth with all doxorubicin groups was slower than that of control (P: <0.0001-0.0069). At the interface of the 200CR film and tumour, there was cellular necrosis, surrounded by apoptotic cells before reaching viable tumour cells.

conclusionsCombining surgical resection and sustained local doxorubicin treatment is effective in tumour control. Administering doxorubicin in a local, controlled manner is superior to giving an equivalent intravenous dose in tumour control.

Indexed as

Adrenal Gland NeoplasmsAnimalsAntibiotics, AntineoplasticCell Line, TumorCombined Modality TherapyDelayed-Action PreparationsDoxorubicinDrug CarriersFemaleHumansMiceMice, Inbred BALB CMice, NudeNeuroblastomaSilkTumor BurdenAntibiotics, AntineoplasticDelayed-Action PreparationsDoxorubicinDrug CarriersSilk

Identifiers

PMID24921912
PMCPMC4134491
OpenAlexW2041588886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.